Last updated: September 30, 2026
AMERGE, the brand name for naratriptan, is a mature triptan migraine medicine with limited remaining commercial value as a branded product. GlaxoSmithKline launched AMERGE in the United States in 1998 after FDA approval for the acute treatment of migraine attacks, with or without aura. Core patent protection expired in the mid-2010s, and generic naratriptan now supplies the market. GSK does not report AMERGE revenue as a standalone product, so its current financial contribution is not publicly measurable and is likely immaterial within the company’s portfolio.
What is AMERGE and who markets naratriptan?
AMERGE contains naratriptan hydrochloride, a selective serotonin 5-HT1B/1D receptor agonist. It is an oral tablet approved for the acute treatment of migraine in adults. The original U.S. strengths were 1 mg and 2.5 mg tablets. The product is not indicated for migraine prevention.
| Attribute |
AMERGE |
| Active ingredient |
Naratriptan hydrochloride |
| Drug class |
Triptan; 5-HT1B/1D receptor agonist |
| Dosage form |
Immediate-release oral tablet |
| U.S. strengths |
1 mg and 2.5 mg |
| Original sponsor |
Glaxo Wellcome, later GlaxoSmithKline |
| U.S. approval |
1998 |
| Indication |
Acute treatment of migraine with or without aura |
| Current commercial model |
Primarily generic naratriptan |
| FDA pathway |
New Drug Application followed by abbreviated new drug applications for generics |
| Biologic status |
Not applicable |
The product’s clinical differentiation came from naratriptan’s relatively long half-life and lower reported recurrence rates than some shorter-acting triptans. Those attributes did not prevent erosion after generic entry or the later migration of prescribing toward newer migraine therapies.
When does AMERGE lose exclusivity and when did generic entry begin?
AMERGE lost meaningful U.S. market exclusivity after expiration of the principal naratriptan patent estate. The core U.S. compound patent, U.S. Patent No. 5,656,600, covered naratriptan-related chemical matter and had an expiration date in 2015 after statutory patent-term adjustments and extensions reflected in public patent records.
| Milestone |
Approximate timing |
Commercial effect |
| FDA approval of AMERGE |
1998 |
Brand launch |
| Core patent protection |
Through mid-2010s |
Protected branded sales |
| Generic naratriptan approvals |
Early 2010s |
Created substitution risk |
| Core patent expiry |
2015 |
Removed principal composition protection |
| Post-expiry market |
2015 onward |
Generic-dominated supply |
Generic launch timing can vary by applicant, dosage strength, Paragraph IV litigation, and settlement terms. The practical commercial change occurred when FDA-approved generic naratriptan became available and pharmacies could substitute it for the branded product.
The five-year New Chemical Entity exclusivity period associated with the original FDA approval expired long before current market competition emerged. Any pediatric exclusivity, if granted, would have added only six months and would not alter the long-term commercial trajectory.
What patents protect AMERGE and naratriptan?
The principal historical patent was U.S. Patent No. 5,656,600, assigned to the original research organization associated with Glaxo. It covered naratriptan and related chemical subject matter. The patent’s expiration removed the central barrier to generic manufacture.
Core patent estate
| Patent |
Subject |
Historical role |
Status |
| U.S. 5,656,600 |
Naratriptan-related chemical compounds |
Principal composition protection |
Expired |
| U.S. and foreign follow-on rights |
Potential process, formulation, or use claims |
Supplemental protection |
No material current barrier identified for U.S. generic supply |
AMERGE did not depend on an extended biologic patent estate, device platform, or complex manufacturing process. Its active ingredient is a small molecule, and generic developers could generally pursue an ANDA rather than a full NDA.
Public patent records and FDA product information should be distinguished. Patent expiration does not by itself prove commercial discontinuation, while an FDA Orange Book listing does not guarantee that a product remains actively marketed.
What is the Orange Book status of AMERGE?
The Orange Book is the relevant U.S. source for approved drug products, therapeutic-equivalence evaluations, and listed patents. AMERGE’s original NDA was approved by FDA, and generic naratriptan products have been approved through the ANDA pathway.
The commercial significance of the Orange Book has declined for AMERGE because the core product patent has expired. Current generic entrants do not face the same composition-of-matter barrier that applied during the branded period. Any remaining listings would need to be assessed by product, strength, dosage form, and NDA or ANDA reference number rather than by the AMERGE brand name alone.
FDA’s Drugs@FDA and Approved Drug Products with Therapeutic Equivalence Evaluations identify approved naratriptan products and their therapeutic-equivalence codes. The Orange Book is also the controlling source for determining whether an active listed patent remains relevant to an ANDA applicant’s certification strategy. (U.S. Food and Drug Administration, n.d.-a, n.d.-b)
Were there Paragraph IV challenges to AMERGE?
Generic naratriptan applicants could use Paragraph IV certifications against unexpired Orange Book patents. The relevant commercial period was the early 2010s, before full erosion of the core patent estate. Publicly documented generic activity indicates that naratriptan faced the standard ANDA challenge process associated with patent expiry.
No current Paragraph IV dispute materially constrains U.S. naratriptan supply. The main legal risk shifted from patent validity to routine generic competition, manufacturing compliance, supply continuity, and pricing.
What formulations are protected by AMERGE patents?
AMERGE was marketed as an immediate-release oral tablet. It did not establish a durable extended-release, injectable, transdermal, orally dissolving, or device-based franchise.
The formulation is commercially vulnerable because:
- The dosage form is a conventional tablet.
- The active ingredient is a small molecule with established synthesis routes.
- Generic manufacturers can replicate the dosage form through ANDA testing.
- There is no major delivery-device barrier comparable to autoinjector or nasal-spray products.
- The product has limited formulation differentiation against other oral triptans.
Any historical formulation or process claims would have had a narrower commercial role than the core compound patent. Once the principal patent expired, formulation claims were unlikely to preserve meaningful branded pricing unless they covered a commercially differentiated product.
What is the FDA regulatory status of AMERGE and generic naratriptan?
AMERGE remains an FDA-approved product based on its original NDA history, but approval status and active commercial distribution are separate issues. Generic naratriptan products are approved under ANDAs and are therapeutically equivalent to the reference product where FDA assigns an applicable equivalence rating.
The label identifies cardiovascular contraindications and warnings typical of the triptan class, including use restrictions in patients with certain coronary artery, cerebrovascular, peripheral vascular, or uncontrolled hypertension conditions. Naratriptan is also subject to class-level prescribing considerations involving serotonin syndrome and drug interactions. (U.S. Food and Drug Administration, 2017)
Regulatory risk is low compared with newer products because the clinical and manufacturing framework is mature. The principal risks are product-quality findings, shortages, manufacturing-site changes, and label compliance rather than approval uncertainty.
How does AMERGE compare with competing migraine drugs?
AMERGE competes in a mature triptan market and a broader migraine market that now includes calcitonin gene-related peptide therapies, ditans, gepants, and established generic drugs.
| Product or class |
Competitive position versus AMERGE |
| Sumatriptan |
Broadest generic availability and strong historical physician familiarity |
| Rizatriptan |
Rapid onset and multiple oral formulations |
| Zolmitriptan |
Oral and nasal delivery options |
| Eletriptan |
Historically positioned around efficacy and potency |
| Frovatriptan |
Longer duration and lower recurrence positioning |
| Ubrogepant and rimegepant |
Non-triptan acute options without the same vasoconstrictive mechanism |
| Lasmiditan |
Non-vasoconstrictive acute treatment, with driving restrictions |
| CGRP monoclonal antibodies |
Preventive rather than acute treatment, with higher-cost branded economics |
AMERGE’s most important competitive disadvantages are generic substitution, limited formulation variety, and the availability of drugs positioned for patients who cannot tolerate or should not receive triptans. Its potential advantages include established clinical familiarity, low generic cost, and a longer duration of action than some shorter-acting tripans.
How strong is the AMERGE patent estate?
The historical estate was commercially strong while composition protection remained active but is weak as a current barrier to entry.
| Factor |
Assessment |
| Composition-of-matter protection |
Expired |
| Formulation differentiation |
Limited |
| Manufacturing complexity |
Moderate but manageable for generic producers |
| Regulatory pathway |
Straightforward ANDA pathway |
| Biosimilar exposure |
None |
| Substitution risk |
High |
| Ability to sustain premium pricing |
Low |
| Litigation leverage |
Low after core patent expiry |
AMERGE has no biosimilar risk because naratriptan is a chemically synthesized small molecule, not a biologic. Its current competitive exposure is generic risk, not biosimilar risk.
What patent litigation and settlement agreements affect AMERGE?
The commercially important litigation window was the period when generic applicants challenged remaining patents before or around the core patent expiry. Once the principal patent expired, the incentive for prolonged litigation declined sharply.
No current AMERGE patent litigation or settlement agreement appears to create a material barrier to generic naratriptan sales in the United States based on the FDA and public patent sources cited here. Historical settlements, if any, would have had value mainly by setting an agreed generic launch date. They would not preserve current branded economics after the underlying patent estate expired.
What is the financial trajectory for AMERGE?
GSK does not separately disclose AMERGE revenue in current annual reports. The product was historically reported within broader prescription medicine or respiratory, cardiovascular, central nervous system, or other product categories, depending on the reporting period. That prevents a reliable standalone revenue series.
The financial trajectory can nevertheless be established:
- AMERGE generated branded prescription revenue after its 1998 approval.
- Sales faced competition from established triptans, especially sumatriptan.
- Generic ANDA activity reduced the product’s pricing power.
- Core patent expiry in the mid-2010s accelerated substitution.
- Branded revenue became commercially immaterial relative to GSK’s major vaccines, specialty medicines, and respiratory products.
- Current naratriptan economics accrue mainly to generic manufacturers through low-price, high-substitution sales.
GSK’s financial reports do not identify AMERGE as a material current revenue driver. (GSK plc, 2023, 2024)
Revenue exposure
| Revenue question |
Assessment |
| Standalone AMERGE revenue disclosed? |
No |
| Current GSK revenue dependence |
Immaterial |
| Exposure to U.S. generic erosion |
Historically significant, now largely realized |
| Royalty opportunity |
Limited after patent expiry |
| Generic manufacturer opportunity |
Volume-driven, low-margin |
| Investor relevance |
Portfolio history rather than growth asset |
What generic launch scenarios exist for AMERGE?
The principal generic launch scenario has already occurred. The U.S. market is likely to remain characterized by multiple ANDA holders, pharmacy substitution, and price competition.
Possible commercial outcomes include:
- Continued generic supply with low unit prices.
- Periodic share shifts caused by wholesaler contracts.
- Temporary price increases if manufacturers exit because of low margins.
- Shortages caused by manufacturing or raw-material disruptions.
- Limited residual branded demand among patients or prescribers with product familiarity.
- Further migration to newer acute migraine medicines among commercially insured patients.
A generic manufacturer would gain scale from supply reliability rather than from patent exclusivity. A branded relaunch would face weak economic logic unless paired with a new delivery system, a differentiated combination, or a new indication.
What geographic coverage does AMERGE have?
AMERGE was commercialized internationally under the naratriptan name and local brand strategies. Patent duration and generic timing varied by jurisdiction. European and other markets generally followed the same pattern: national or regional patent expiry led to generic erosion, while reimbursement systems and prescription practices determined the pace.
The United States remains the most relevant market for Orange Book, Paragraph IV, and ANDA analysis. International commercial value depends on local marketing authorization status, national patent registers, reimbursement, and whether the original brand remains actively supplied.
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are operational rather than exclusionary. Naratriptan production requires compliant active pharmaceutical ingredient sourcing, validated tablet manufacturing, analytical testing, packaging, and regulatory documentation. Those requirements can exclude poorly capitalized suppliers but do not prevent established generic companies from entering.
The strongest remaining barriers are:
- FDA manufacturing compliance.
- Reliable API sourcing.
- Bioequivalence and quality testing.
- Supply-chain scale.
- Wholesaler and pharmacy access.
- Ability to operate profitably at generic prices.
No current intellectual-property barrier comparable to a live composition patent has been identified for U.S. naratriptan.
Key Takeaways
- AMERGE is the branded form of naratriptan, an oral triptan approved by FDA in 1998.
- Its principal U.S. composition patent, U.S. Patent No. 5,656,600, expired in the mid-2010s.
- Generic naratriptan has replaced the branded product as the main commercial supply.
- GSK does not report AMERGE revenue separately, and the product is not a material current revenue driver.
- The product has no biosimilar exposure because it is a small-molecule drug.
- Current risks relate to generic pricing, manufacturing reliability, and competition from CGRP therapies and other non-triptan migraine drugs.
- The patent estate has little current exclusionary strength.
- A new commercial opportunity would require meaningful formulation, delivery, or clinical differentiation.
FAQs About AMERGE Patent Expiry and Market Economics
Is AMERGE still sold in the United States?
Generic naratriptan is the principal U.S. supply. Availability of the original AMERGE brand can vary by distributor and manufacturer marketing decisions.
Does AMERGE have pediatric exclusivity?
The commercially important exclusivity period has expired. Any historical pediatric exclusivity would not affect current generic competition.
Is naratriptan a controlled substance?
No. Naratriptan is not classified as a controlled substance under the U.S. Controlled Substances Act.
Can a company launch a new naratriptan formulation without a new patent?
Yes. A company could pursue an eligible regulatory pathway for a differentiated formulation, but commercial protection would depend on new intellectual-property claims, regulatory exclusivity, clinical differentiation, and reimbursement.
What is the main investment risk associated with AMERGE?
The primary risk is that the product has already undergone patent and generic erosion. Current revenue potential is limited unless a company creates a differentiated product with enforceable new protection.
References
- GlaxoSmithKline plc. (2023). Annual report 2022. https://www.gsk.com
- GlaxoSmithKline plc. (2024). Annual report 2023. https://www.gsk.com
- U.S. Food and Drug Administration. (2017). Amerge (naratriptan hydrochloride) tablets prescribing information. https://www.accessdata.fda.gov
- U.S. Food and Drug Administration. (n.d.-a). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
- U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
- U.S. Patent and Trademark Office. (n.d.). Patent Center. https://patentcenter.uspto.gov
- U.S. Patent No. 5,656,600. (1997). 5,6,7,8-Tetrahydro-4H-pyrido[1,2-a][1,2,4]triazin-4-one derivatives. U.S. Patent and Trademark Office.
